Article
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.
Critical reviews in oncology/hematology - 1 Apr 2021
Zhao Yi, Cheng Bo, Chen Zisheng, Li Jianfu, Liang Hengrui, Chen Ying, Zhu Feng, Li Caichen, Xu Ke, Xiong Shan, Lu Weixiang, Chen Zhuxing, Zhong Ran, Zhao Shen, Xie Zhanhong, Liu Jun, Liang Wenhua, He Jianxing
Abstract excerpt
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and spectrum (involving various specific adverse events) of each EGFR-TKI are of particular clinical interest and importance. Data from phase II and III randomized controlled trials comparing treatments among EGFR-TKIs (osimertinib,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.